✦ LIBER ✦

UPFRONT CLOPIDOGREL USE AND THE EFFICACY AND SAFETY OF EARLY EPTIFIBATIDE USE IN PATIENTS WITH ACUTE CORONARY SYNDROME: AN ANALYSIS FROM THE EARLY VERSUS DELAYED PROVISIONAL EPTIFIBATIDE IN ACUTE CORONARY SYNDROMES (EARLY ACS) TRIAL

✍ Scribed by Tracy Wang; Jennifer A. White; Robert P. Giugliano; Pierluigi Tricoci; Robert A. Harrington; Gilles Montalescot; Uwe Zeymer; Frans Van de Werf; Paul W. Armstrong; Eugene Braunwald; Robert M. Califf; L. Kristin Newby

Book ID: 118580033
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 87 KB
Volume: 55
Category: Article
ISSN: 1558-3597
DOI: 10.1016/s0735-1097(10)60452-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Association between smoking, outcomes, a

Association between smoking, outcomes, and early clopidogrel use in patients with acute coronary syndrome: Insights from the Global Registry of Acute Coronary Events

✍ Matthew Sibbald; Andrew T. Yan; Wei Huang; Keith A.A. Fox; Joel M. Gore; Ph. Gab 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 133 KB

The Early Glycoprotein IIb/IIIa Inhibiti

The Early Glycoprotein IIb/IIIa Inhibition in Non–ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial: A randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non–ST-segment elevation acute coronary syndrome—Study design and rationale

✍ Robert P. Giugliano; L. Kristin Newby; Robert A. Harrington; C. Michael Gibson; 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 148 KB

EVALUATION OF THE EFFICACY AND SAFETY OF

EVALUATION OF THE EFFICACY AND SAFETY OF OTAMIXABAN VS. UNFRACTIONATED HEPARIN+EPTIFIBATIDE IN ELDERLY PATIENTS WITH NON-ST-ELEVATION ACUTE CORONARY SYNDROMES IN THE SEPIA-ACS1 TIMI 42 TRIAL

✍ Christian T. Ruff; Shaun Goodman; Hanoch Hod; Christoph Bode; Petr Widimsky; Rob 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 292 KB

Efficacy and Safety of Fondaparinux Vers

Efficacy and Safety of Fondaparinux Versus Enoxaparin in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: Results From the OASIS-5 Trial

✍ Shamir R. Mehta; Christopher B. Granger; John W. Eikelboom; Jean-Pierre Bassand; 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 609 KB

Design and rationale of the Treatment of

Design and rationale of the Treatment of Acute Coronary Syndromes with Otamixaban trial: A double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non–ST-segment elevation acute coronary syndromes with a planned early invasive strategy

✍ Philippe Gabriel Steg; Shamir R. Mehta; Charles V. Pollack Jr.; Christoph Bode; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 398 KB

Has the ClOpidogrel and Metoprolol in My

Has the ClOpidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early β-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE)

✍ Jeremy Edwards; Shaun G. Goodman; Raymond T. Yan; Robert C. Welsh; Jan M. Kornde 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 280 KB